GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MoonLake Immunotherapeutics (NAS:MLTX) » Definitions » Cash Ratio

MoonLake Immunotherapeutics (MoonLake Immunotherapeutics) Cash Ratio : 61.39 (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is MoonLake Immunotherapeutics Cash Ratio?

The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. MoonLake Immunotherapeutics's Cash Ratio for the quarter that ended in Mar. 2024 was 61.39.

MoonLake Immunotherapeutics has a Cash Ratio of 61.39. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.

The historical rank and industry rank for MoonLake Immunotherapeutics's Cash Ratio or its related term are showing as below:

MLTX' s Cash Ratio Range Over the Past 10 Years
Min: 0.38   Med: 24.04   Max: 70.33
Current: 61.39

During the past 3 years, MoonLake Immunotherapeutics's highest Cash Ratio was 70.33. The lowest was 0.38. And the median was 24.04.

MLTX's Cash Ratio is ranked better than
99.34% of 1525 companies
in the Biotechnology industry
Industry Median: 2.85 vs MLTX: 61.39

MoonLake Immunotherapeutics Cash Ratio Historical Data

The historical data trend for MoonLake Immunotherapeutics's Cash Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MoonLake Immunotherapeutics Cash Ratio Chart

MoonLake Immunotherapeutics Annual Data
Trend Dec21 Dec22 Dec23
Cash Ratio
0.38 9.41 51.28

MoonLake Immunotherapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.66 70.33 48.12 51.28 61.39

Competitive Comparison of MoonLake Immunotherapeutics's Cash Ratio

For the Biotechnology subindustry, MoonLake Immunotherapeutics's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MoonLake Immunotherapeutics's Cash Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MoonLake Immunotherapeutics's Cash Ratio distribution charts can be found below:

* The bar in red indicates where MoonLake Immunotherapeutics's Cash Ratio falls into.



MoonLake Immunotherapeutics Cash Ratio Calculation

The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.

MoonLake Immunotherapeutics's Cash Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash Ratio (A: Dec. 2023 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=511.008/9.966
=51.28

MoonLake Immunotherapeutics's Cash Ratio for the quarter that ended in Mar. 2024 is calculated as:

Cash Ratio (Q: Mar. 2024 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=547.055/8.911
=61.39

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


MoonLake Immunotherapeutics  (NAS:MLTX) Cash Ratio Explanation

The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.

The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.

In general, the higher the cash ratio, the better the company's liquidity position.


MoonLake Immunotherapeutics Cash Ratio Related Terms

Thank you for viewing the detailed overview of MoonLake Immunotherapeutics's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


MoonLake Immunotherapeutics (MoonLake Immunotherapeutics) Business Description

Traded in Other Exchanges
Address
Dorfstrasse 29, Zug, CHE, 6300
MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company engaged in leveraging Nanobody technology to develop next-level medicines for immunologic diseases, including inflammatory skin and joint diseases.
Executives
Matthias Bodenstedt officer: Chief Financial Officer DORFSTRASSE 29, ZUG V8 6300
Bihua Chen 10 percent owner C/O CORMORANT ASSET MANAGEMENT, LP, 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Private Healthcare Fund Iv Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Asset Management, Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Global Healthcare Master Fund, Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Private Healthcare Fund Iii Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Private Healthcare Fund Ii, Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Simon Sturge director DORFSTRASSE 29, ZUG V8 6300
Kristian Reich officer: Chief Scientific Officer DORFSTRASSE 29, ZUG V8 6300
Santos Da Silva Jorge director, officer: Chief Executive Officer DORFSTRASSE 29, ZUG V8 6300
Bvf Partners L P/il director, 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Andrew John Phillips director C/O CORMORANT ASSET MANAGEMENT, LLP, 200 CLARENDON STREET, FL 52, BOSTON MA 02116
Ramnik Xavier director DORFSTRASSE 29, ZUG V8 6300
Spike Loy director DORFSTRASSE 29, ZUG V8 6300
Kara Lassen director DORFSTRASSE 29, ZUG V8 6300

MoonLake Immunotherapeutics (MoonLake Immunotherapeutics) Headlines

From GuruFocus